Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | POLB | P06746 | 5/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.74 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143685 | 1.00 | MEN1 (0.74) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL7145550 | 0.95 | AKR1B1 (0.72) | MEN1POLBKMT2AGFERAKR1B1 | |
| SCHEMBL7145553 | 0.95 | AKR1B1 (0.72) | MEN1POLBKMT2AGFERAKR1B1 | |
| SCHEMBL7149398 | 0.94 | POLB (0.73) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL7149394 | 0.94 | POLB (0.73) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL7148330 | 0.94 | POLB (0.68) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL7148334 | 0.94 | POLB (0.68) | MEN1POLBKMT2APLA2G1BDNMT1 | |
| SCHEMBL7144793 | 0.92 | AKR1B1 (0.77) | GFERAKR1B1PTPN1PTPN2ADAMTS5 | |
| SCHEMBL7144796 | 0.92 | AKR1B1 (0.77) | GFERAKR1B1PTPN1PTPN2ADAMTS5 | |
| SCHEMBL7145492 | 0.91 | POLB (0.81) | MEN1POLBKMT2APLA2G1BDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6506755-B2 | 5-((2,4-bis-(4-methylphenylmethoxy)phenyl)methylene)-4-oxo-2-thioxo-3 -thiazolidineacetic acid, for example; treatment and prophylaxis of tumors and tumor metastasis | HOFFMANN-LA ROCHE INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020037901-A1 | Thiazolidinecarboxyl acids | HOFFMANN-LA ROCHE INC. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037901-A1 | Thiazolidinecarboxyl acids | TPMT, NAT1, THRA | MEN1 936/4885POLB 3974/4885KMT2A 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.